Athersys, Inc. - ATHX STOCK NEWS

Athersys (NASDAQ: ATHX) and Healios K.K. announced a strengthened partnership to enhance the development and commercialization of MultiStem® in Japan. The collaboration aims to improve regulatory approval processes and expand commercial manufacturing capabilities. Key agreements include Healios gaining access to Athersys’s manufacturing technology and sharing investment in commercial preparation. The partnership also introduces $8 million in potential milestone payments for Athersys linked to Japanese manufacturing activities, marking a significant step toward achieving regulatory success and delivering innovative therapies to patients.

Athersys, Inc. (Nasdaq: ATHX) is set to release its second quarter 2021 financial results on August 9, 2021, at 4:00 PM Eastern Time. Following the results, a conference call will be held at 4:30 PM to discuss the outcomes. Shareholders can join via a webcast or by phone after registering. A replay will be available shortly after the call, providing further insights for investors.

Athersys, Inc. (NASDAQ: ATHX) has published important findings in the journal Scientific Reports, highlighting the role of Multipotent Adult Progenitor Cells (MAPC^®), known as MultiStem^®, in modulating inflammation. The research outlines how MAPC cells can enhance regulatory T cell (Treg) differentiation and function, which is crucial in managing inflammation post-injury. Athersys is currently conducting three clinical studies for MultiStem in treating ischemic stroke, ARDS, and severe trauma, with supportive data reinforcing the efficacy of its cell therapy approach.

Athersys reported its Q1 2021 financial results, revealing a net loss of $26.5 million ($0.13 per share), an increase from a loss of $15.6 million in Q1 2020. The company had no revenue for the quarter, and R&D expenses rose to $17.5 million, driven by clinical trial costs. General and administrative expenses also increased to $8.8 million, mainly due to legal costs related to a settlement and executive changes. Athersys ended the quarter with $64.2 million in cash, up from $51.5 million at the end of 2020, and looks forward to results from the TREASURE and ONE-BRIDGE studies in Japan.

Ivor Macleod, CFO of Athersys (NASDAQ: ATHX), will present at the Bank of America Securities 2021 Virtual Health Care Conference on May 12, 2021, at 12:30 PM EDT. The event includes a corporate update followed by a Q&A session with a Bank of America analyst. Virtual meetings with institutional representatives will also take place. A live webcast will be available on Athersys' website, with a replay accessible 24 hours post-event. Athersys specializes in biotechnology, focusing on the MultiStem® cell therapy for various medical conditions.

Athersys, Inc. (Nasdaq: ATHX) is set to release its first quarter 2021 financial results on May 6, 2021, at 4:00 PM ET, followed by a conference call at 4:30 PM ET. The call will be hosted by management and will include a review of the financial results. Shareholders can register for the call using the provided links for both webcast and phone access. A replay of the event will be available on Athersys' website approximately two hours after the call concludes. Athersys focuses on developing its MultiStem® cell therapy for various critical care indications.

Athersys, Inc. (NASDAQ: ATHX) announced that CFO Ivor Macleod will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 1:30 PM EDT. A live webcast can be accessed via the company’s website, and an archived replay will be available post-conference. The company invites institutional investors interested in virtual meetings with management to contact the conference coordinators. Athersys focuses on developing its proprietary MultiStem® cell therapy for various critical health issues, supported by strategic partnerships.

Athersys, Inc. (Nasdaq: ATHX) announced the completion of enrollment in the ONE-BRIDGE study by partner HEALIOS K.K. in Japan, assessing MultiStem^® (invimestrocel) for acute respiratory distress syndrome (ARDS) linked to pneumonia. The trial includes two cohorts: 30 patients with pneumonia-induced ARDS and 5 with COVID-19 induced ARDS. Athersys is also conducting the MACOVIA trial in the U.S. for ARDS, which received FDA's Fast Track and RMAT designations. ARDS poses high treatment costs, and effective therapies could significantly improve patient outcomes.

Athersys, Inc. (NASDAQ: ATHX) reported its fourth quarter and annual 2020 financial results, highlighting significant advancements despite challenging conditions. The company progressed in large-scale manufacturing and accelerated the MultiStem therapy development for ARDS amid the COVID-19 pandemic with the MACOVIA study. Key partnerships in Japan with Healios are set to bolster commercialization efforts. Athersys anticipates top-line results from the TREASURE and ONE-BRIDGE studies, pivotal for ischemic stroke treatment, in 2021.